Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. Osprey’s proprietary DyeVert PLUS contrast reduction system reduces the amount of contrast (dye) used in angiography procedures. For many patients this dye is safe however, in patients with poor kidney function, the dye used can be harmful and induce acute kidney injury (AKI). The DyeVert PLUS system reduces contrast to safe levels without compromising imaging quality.
Osprey is ASX-listed and based in Minnesota, USA. The DyeVert PLUS system is FDA-approved and CE marked, and the company has seen steady and sustainable revenue growth in the US market.
Find out more at ospreymed.com
Company’s Keywords:
<0
<100000000
<
<
Your request has been submitted successfully.
Own or work here?